LRG1 Antibody (H-8): sc-514316

LRG1 Antibody (H-8) is a mouse monoclonal IgG3 antibody that detects LRG1 in mouse and rat samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). LRG1, or leucine-rich alpha-2-glycoprotein, is a 347 amino acid secreted protein characterized by eight leucine-rich repeats and one LRRCT domain, which play a crucial role in protein-protein interactions, signal transduction, cell adhesion, and developmental processes. LRG1 is predominantly found in plasma and is notably expressed during granulocyte differentiation, highlighting its importance in immune response and inflammation. The gene encoding LRG1 is located on human chromosome 19p13.3, a region known for its high gene density, containing approximately 1,400 genes, including several members of the immunoglobulin superfamily. This chromosomal location houses genes vital for immune function, such as killer cell and leukocyte immunoglobulin-like receptors, as well as various intercellular adhesion molecules. The intricate structure of LRG1, with its multiple leucine-rich repeats, is essential for biological activity, allowing effective mediation of interactions critical for cellular communication and immune regulation. Anti-LRG1 antibody (H-8) serves as an invaluable tool for researchers studying LRG1′s roles in health and disease, particularly in immune responses and granulocyte function.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

LRG1 Antibody (H-8) References:

1. LRG1 is an independent prognostic factor for endometrial carcinoma.  |  Wen, SY., et al. 2014. Tumour Biol. 35: 7125-33. PMID: 24760273
2. LRG1 suppresses the migration and invasion of hepatocellular carcinoma cells.  |  Zhang, Y., et al. 2015. Med Oncol. 32: 146. PMID: 25814288
3. LRG1 expression indicates unfavorable clinical outcome in hepatocellular carcinoma.  |  Wang, CH., et al. 2015. Oncotarget. 6: 42118-29. PMID: 26517349
4. LRG1 modulates epithelial-mesenchymal transition and angiogenesis in colorectal cancer via HIF-1α activation.  |  Zhang, J., et al. 2016. J Exp Clin Cancer Res. 35: 29. PMID: 26856989
5. Role of VEGF-A and LRG1 in Abnormal Angiogenesis Associated With Diabetic Nephropathy.  |  Zhang, A., et al. 2020. Front Physiol. 11: 1064. PMID: 32982792
6. LRG1 Mitigates Renal Interstitial Fibrosis through Alleviating Capillary Rarefaction and Inhibiting Inflammatory and Pro-Fibrotic Cytokines.  |  Liu, TT., et al. 2021. Am J Nephrol. 52: 228-238. PMID: 33823527
7. LRG1 facilitates corneal fibrotic response by inducing neutrophil chemotaxis via Stat3 signaling in alkali-burned mouse corneas.  |  Yu, B., et al. 2021. Am J Physiol Cell Physiol. 321: C415-C428. PMID: 34260299
8. Latrophilin-2 is a novel receptor of LRG1 that rescues vascular and neurological abnormalities and restores diabetic erectile function.  |  Yin, GN., et al. 2022. Exp Mol Med. 54: 626-638. PMID: 35562586
9. Increased LRG1 Levels in Overweight and Obese Adolescents and Its Association with Obesity Markers, Including Leptin, Chemerin, and High Sensitivity C-Reactive Protein.  |  Alhammad, R., et al. 2022. Int J Mol Sci. 23: PMID: 35955698
10. LRG1-Targeted Nintedanib Delivery for Enhanced Renal Fibrosis Mitigation.  |  Zhang, Y., et al. 2024. Nano Lett. 24: 11097-11107. PMID: 39185720

The preferred LRG1 antibody is LRG1 Antibody (C-4): sc-390920.